Incyte Corporation - Product Pipeline Review - 2016

Published: May, 2016 | Pages: 84 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Incyte Corporation - Product Pipeline Review - 2016

Summary

Global Markets Direct's, 'Incyte Corporation - Product Pipeline Review - 2016', provides an overview of the Incyte Corporation's pharmaceutical research and development focus. 

The report provides comprehensive information on the therapeutics under development by Incyte Corporation, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the pipeline therapeutic landscape of Incyte Corporation
- The report provides overview of Incyte Corporation including its business description, key facts, and locations and subsidiaries
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report assesses Incyte Corporation's pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report features Incyte Corporation's out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons To Buy

- Evaluate Incyte Corporation's strategic position with total access to detailed information on its product pipeline
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Incyte Corporation
- Identify potential new clients or partners in the target demographic
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Incyte Corporation's pipeline depth and focus of pipeline therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

 Table of Contents

Table of Contents 2
List of Tables 5
List of Figures 5
Incyte Corporation Snapshot 6
Incyte Corporation Overview 6
Key Information 6
Key Facts 6
Incyte Corporation - Research and Development Overview 7
Key Therapeutic Areas 7
Incyte Corporation - Pipeline Review 13
Pipeline Products by Stage of Development 13
Pipeline Products - Monotherapy 14
Pipeline Products - Combination Treatment Modalities 15
Pipeline Products - Partnered Products 16
Partnered Products/Combination Treatment Modalities 17
Pipeline Products - Out-Licensed Products 18
Out-Licensed Products/Combination Treatment Modalities 19
Incyte Corporation - Pipeline Products Glance 20
Incyte Corporation - Clinical Stage Pipeline Products 20
Phase II Products/Combination Treatment Modalities 20
Phase I Products/Combination Treatment Modalities 21
Incyte Corporation - Early Stage Pipeline Products 22
IND/CTA Filed Products/Combination Treatment Modalities 22
Preclinical Products/Combination Treatment Modalities 23
Discovery Products/Combination Treatment Modalities 24
Incyte Corporation - Drug Profiles 25
(INCB-039110 + INCB-040093) 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
epacadostat 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
INCB-40093 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
itacitinib adipate 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
ruxolitinib phosphate 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
INCB-50465 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
INCB-52793 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
INCB-53914 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
INCB-54329 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
INCB-54828 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
INCB-59872 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
SHR-1210 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
INCAGN-1876 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
INCAGN-1949 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
INCB-57643 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
Monoclonal Antibody to Inhibit LAG3 for Oncology 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
Monoclonal Antibody to Inhibit TIM3 for Oncology 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
Small Molecule for Oncology 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
Small Molecules for Chronic Inflammation 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
Incyte Corporation - Pipeline Analysis 52
Incyte Corporation - Pipeline Products by Target 52
Incyte Corporation - Pipeline Products by Route of Administration 54
Incyte Corporation - Pipeline Products by Molecule Type 55
Incyte Corporation - Pipeline Products by Mechanism of Action 56
Incyte Corporation - Recent Pipeline Updates 58
Incyte Corporation - Dormant Projects 75
Incyte Corporation - Discontinued Pipeline Products 76
Discontinued Pipeline Product Profiles 76
aderbasib 76
INCB-047986 76
itacitinib adipate 76
ruxolitinib phosphate 76
Incyte Corporation - Company Statement 78
Incyte Corporation - Locations And Subsidiaries 82
Head Office 82
Other Locations & Subsidiaries 82
Appendix 83
Methodology 83
Coverage 83
Secondary Research 83
Primary Research 83
Expert Panel Validation 83
Contact Us 83
Disclaimer 84

List of Tables

Incyte Corporation, Key Information 6
Incyte Corporation, Key Facts 6
Incyte Corporation - Pipeline by Indication, 2016 8
Incyte Corporation - Pipeline by Stage of Development, 2016 13
Incyte Corporation - Monotherapy Products in Pipeline, 2016 14
Incyte Corporation - Combination Treatment Modalities in Pipeline, 2016 15
Incyte Corporation - Partnered Products in Pipeline, 2016 16
Incyte Corporation - Partnered Products/ Combination Treatment Modalities, 2016 17
Incyte Corporation - Out-Licensed Products in Pipeline, 2016 18
Incyte Corporation - Out-Licensed Products/ Combination Treatment Modalities, 2016 19
Incyte Corporation - Phase II, 2016 20
Incyte Corporation - Phase I, 2016 21
Incyte Corporation - IND/CTA Filed, 2016 22
Incyte Corporation - Preclinical, 2016 23
Incyte Corporation - Discovery, 2016 24
Incyte Corporation - Pipeline by Target, 2016 53
Incyte Corporation - Pipeline by Route of Administration, 2016 54
Incyte Corporation - Pipeline by Molecule Type, 2016 55
Incyte Corporation - Pipeline Products by Mechanism of Action, 2016 56
Incyte Corporation - Recent Pipeline Updates, 2016 58
Incyte Corporation - Dormant Developmental Projects,2016 75
Incyte Corporation - Discontinued Pipeline Products, 2016 76
Incyte Corporation, Subsidiaries 82